Abstract：Objective To observe the effect of Shugan Jieyu Capsules combined with antidepressant in the treatment of post-stroke depression. Methods From July 2016 to July 2018, 128 patients with post-stroke depression (PSD) treated in the Inner Mongolia Mental Health Center were selected and divided into control group and observation group according to random number table method, with 64 patients in each group. The control group received conventional antidepressant treatment, and the observation group was treated with Shugan Jieyu Capsules on the basis of antidepressant. Both groups were treated for 6 weeks. Hamilton depression rating scale (HAMD) was used to evaluate the efficacy and depression degree. Neurological function was assessed using the National Institutes of health stroke scale (NIHSS). Quality of life was assessed by referring to the nurses′ observation scale for inpatient evaluation (NOSIE). Adverse reactions were observed in the two groups. Results The total effective rate of observation group was significantly higher than control group (P ＜ 0.01). After 6 weeks, the NIHSS score of the observation group was lower than that of the control group, and the difference was highly statistically significant (P ＜ 0.01). HAMD scores in the observation group after 6 weeks were lower than those in the control group (P ＜ 0.01). There was no statistically significant difference in the rate of adverse reactions between the two groups (P ＞ 0.05). Both groups showed mild nausea, headache, constipation and other reactions, which spontaneously subsided after 2-3 days. The scores of depression, personal hygiene, social interest and social ability of the observation group were lower than those of the control group (P ＜ 0.01). Conclusion The combined treatment of Shugan Jieyu Capsules and antidepressant for PSD has a definite effect, which can relieve the symptoms of depression, improve neurological function and the quality of life. Only mild headache, nausea and other reactions occur, with no serious adverse reactions, it is safe and effective.
田乐 张慧如 王毅 王建俊 倪晶晶 景兰▲. 舒肝解郁胶囊联合抗抑郁药治疗脑卒中后抑郁症的效果[J]. 中国医药导报, 2019, 16(20): 80-83.
TIAN Le ZHANG Huiru WANG Yi WANG Jianjun NI Jingjing JING Lan▲. Effects of Shugan Jieyu Capsules combined with antidepressant in the treatment of post-stroke depression. 中国医药导报, 2019, 16(20): 80-83.
[1] 杜杨文，刘泰.理气法治疗卒中后抑郁的研究进展[J].中西医结合心脑血管病杂志，2018，16（17）：2514-2516.
[2] 解恒革.重视对脑卒中后认知障碍和抑郁的研究[J].中华老年心脑血管病杂志，2018，20（10）：1009-1011.
[3] 满晓静，颜晗，孙嘉利.卒中后抑郁的研究进展[J].实用医药杂志，2018，35（10）：946-948
[4] Lewin-Richter A，Volz M，J?觟bges M，et al. Predictivity of early depressive symptoms for post-stroke depression [J]. J Nutr Health Aging，2015，19（7）：754-758.
[5] 饶明俐.中国脑血管病防治指南编写委员会.中国脑血管病防治指南：试行版[M].北京：人民卫生出版社，2007：21-67.
[6] 陈方彦.CCMD-3中国精神障碍分类与诊断标准[M].济南：山东科学技术出版社，2001：87-88.
[7] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，1994.
[8] 蔡红慧，祝炳军.乌灵胶囊联合抗抑郁药治疗脑卒中后抑郁症临床疗效及对神经功能的影响[J].中华中医药学刊，2016，34（10）：2548-2550.
[9] 成加林，许晴丽，王又桂.脑卒中后抑郁症患者神经功能康复治疗临床研究[J].中外医学研究，2018，16（8）：40-41.
[10] 谢艳，夏琳，徐艳祥，等.氟哌噻吨美利曲辛联合解郁安神颗粒治疗脑卒中后抑郁症的临床研究[J].安徽医药，2017，21（6）：1120-1123.
[11] 何喜美，向华.艾地苯醌对缺血性脑卒中后抑郁症患者血清炎性因子和生活质量的影响[J].解放军医药杂志，2018，30（6）：96-99.
[12] Valiengo L，Casati R，Bolognini N，et al. Transcranial direct current stimulation for the treatment of post-stroke depression in aphasic patients：a case series [J]. Neurocase，2016，22（2）：225-228.
[13] Imarhiagbe F，Afolabi O，Kubeyinje A，et al. Post-stroke depression （PSD） in sub-Saharan Africans- validation of the Japanese stroke scale for depression.（JSS-D）（P7.129） [J]. Josanpu Zasshi，2015，23（7）：653-667.
[14] Wichowicz HM，G?諭secki D，Landowski J，et al. Clinical utility of chosen factors in predicting post-stroke depression：a one year follow-up [J]. Psychiatr Pol，2015，49（4）：683-696.
[15] Nishida N，Hata Y，Yoshida K，et al. Neuropathologic features of suicide victims who presented with acute poststroke depression：significance of association with neurodegenerative disorders [J]. J Neuropathol Exp Neurol，2015，74（5）：401-410.
[16] Karakus K，Kunt R，Memis CO，et al. The factors related to early-onset depression after first stroke [J]. Psychogeriatrics，2017，17（6）：414-422.
[17] Ibeneme SC，Nwosu AO，Ibeneme GC，et al. Distribution of symptoms of post-stroke depression in relation to some characteristics of the vulnerable patients in socio-cultural context [J]. Afr Health Sci，2017，17（1）：70-78.
[18] Vojtikivsamoilovska D，Arsovska A. Prevalence and Predictors of Depression after Stroke - Results from a Prospective Study [J]. Open Access Maced J Med Sci，2018，6（5）：824-828.
[19] 汪昆.盐酸帕罗西汀对治疗脑卒中后抑郁的临床作用研究[J].陕西医学杂志，2016，45（4）：490-491.
[20] 付长永，蒋慧，王浩，等.痒觉刺激对脑卒中后抑郁的临床疗效观察[J].中国现代医生，2017，55（32）：93-96.
[21] 刘得水，李丽波，荣华，等.艾司西酞普兰联合黛力新治疗卒中后抑郁患者临床疗效分析[J].中国医药科学，2018， 8（20）：17-20.
[22] 王小华，王钧，尹琪华.奥沙西泮联合黛力新治疗49例脑卒中后抑郁的疗效及预后研究[J].中华全科医学，2016， 14（6）：976-978.
[23] 文军，李永涛，李淼，等.米氮平片联合舒肝解郁胶囊对脑卒中后抑郁症患者神经功能的影响[J].河北医药，2015， 37（8）：1203-1205.
[24] 胡宏伟，石灯汉.舒肝解郁胶囊联合自拟通络汤治疗风痰瘀阻型脑卒中后抑郁症[J].中华中医药杂志，2017， 32（6）：2818-2820.
[25] Babkair LA. Risk Factors for Poststroke Depression：An Integrative Review [J]. J Neurosci Nurs，2017，49（2）：73.
[26] Amaricai E，Poenaru DV. The post-stroke depression and its impact on functioning in young and adult stroke patients of a rehabilitation unit [J]. J Mental Health，2016， 25（2）：137.
[27] 侯吉星，权乾坤.舒肝解郁胶囊对轻中度脑卒中后抑郁患者神经认知功能的疗效分析[J].陕西中医，2016，37（7）：817-818.
2019, Vol. 16 
京公网安备 11010502046598号